Modern therapeutic approaches for the treatment of malignant liver tumours.
Journal
Nature reviews. Gastroenterology & hepatology
ISSN: 1759-5053
Titre abrégé: Nat Rev Gastroenterol Hepatol
Pays: England
ID NLM: 101500079
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
accepted:
05
05
2020
pubmed:
19
7
2020
medline:
22
1
2021
entrez:
19
7
2020
Statut:
ppublish
Résumé
Malignant liver tumours include a wide range of primary and secondary tumours. Although surgery remains the mainstay of curative treatment, modern therapies integrate a variety of neoadjuvant and adjuvant strategies and have achieved dramatic improvements in survival. Extensive tumour loads, which have traditionally been considered unresectable, are now amenable to curative treatment through systemic conversion chemotherapies followed by a variety of interventions such as augmentation of the healthy liver through portal vein occlusion, staged surgeries or ablation modalities. Liver transplantation is established in selected patients with hepatocellular carcinoma but is now emerging as a promising option in many other types of tumour such as perihilar cholangiocarcinomas, neuroendocrine or colorectal liver metastases. In this Review, we summarize the available therapies for the treatment of malignant liver tumours, with an emphasis on surgical and ablative approaches and how they align with other therapies such as modern anticancer drugs or radiotherapy. In addition, we describe three complex case studies of patients with malignant liver tumours. Finally, we discuss the outlook for future treatment, including personalized approaches based on molecular tumour subtyping, response to targeted drugs, novel biomarkers and precision surgery adapted to the specific tumour.
Identifiants
pubmed: 32681074
doi: 10.1038/s41575-020-0314-8
pii: 10.1038/s41575-020-0314-8
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
755-772Références
Clavien, P. A., Petrowsky, H., DeOliveira, M. L. & Graf, R. Strategies for safer liver surgery and partial liver transplantation. N. Engl. J. Med. 356, 1545–1559 (2007). This review indicates the significance of safer strategies in liver surgery and partial liver transplantation and highlights tissue augmentation approaches by portal vein embolization and two-stage hepatectomy.
pubmed: 17429086
doi: 10.1056/NEJMra065156
Cabibbo, G., Latteri, F., Antonucci, M. & Craxi, A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 6, 159–169 (2009).
pubmed: 19190599
doi: 10.1038/ncpgasthep1357
Cassidy, S. & Syed, B. A. Colorectal cancer drugs market. Nat. Rev. Drug Discov. 16, 525–526 (2017).
pubmed: 28529321
doi: 10.1038/nrd.2017.59
Adam, R. et al. 2018 annual report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. Transpl. Int. 31, 1293–1317 (2018).
pubmed: 30259574
doi: 10.1111/tri.13358
Bismuth, H. et al. Hepatic transplantation in Europe. First report of the European Liver Transplant Registry. Lancet 2, 674–676 (1987).
pubmed: 2887952
doi: 10.1016/S0140-6736(87)92453-6
Sapisochin, G., et al. Transplant oncology in primary and metastatic liver tumor: principles, evidence and opportunities. Ann. Surg. https://doi.org/10.1097/SLA.0000000000004071 (2020).
Ignatavicius, P. et al. Choices of therapeutic strategies for colorectal liver metastases among expert liver surgeons. A throw of the dice? Ann. Surg. https://doi.org/10.1097/SLA.0000000000004331 (2020).
Jarnagin, W. R. et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann. Surg. 236, 397–406 (2002).
pubmed: 12368667
pmcid: 1422593
doi: 10.1097/00000658-200210000-00001
Poon, R. T. et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann. Surg. 240, 698–708 (2004).
pubmed: 15383797
pmcid: 1356471
Smyrniotis, V., Kostopanagiotou, G., Theodoraki, K., Tsantoulas, D. & Contis, J. C. The role of central venous pressure and type of vascular control in blood loss during major liver resections. Am. J. Surg. 187, 398–402 (2004).
pubmed: 15006570
doi: 10.1016/j.amjsurg.2003.12.001
Pringle, J. H. V. Notes on the arrest of hepatic hemorrhage due to trauma. Ann. Surg. 48, 541–549 (1908).
pubmed: 17862242
pmcid: 1406963
doi: 10.1097/00000658-190810000-00005
Lesurtel, M., Selzner, M., Petrowsky, H., McCormack, L. & Clavien, P. A. How should transection of the liver be performed?: a prospective randomized study in 100 consecutive patients: comparing four different transection strategies. Ann. Surg. 242, 814–822 (2005).
pubmed: 16327491
pmcid: 1409877
doi: 10.1097/01.sla.0000189121.35617.d7
Couinaud, C. Liver lobes and segments: notes on the anatomical architecture and surgery of the liver [In French]. Presse Med. 62, 709–712 (1954).
pubmed: 13177441
Frilling, A. & Clift, A. K. Surgical approaches to the management of neuroendocrine liver metastases. Endocrinol. Metab. Clin. North Am. 47, 627–643 (2018).
pubmed: 30098720
doi: 10.1016/j.ecl.2018.04.001
Sano, K. et al. Outcomes of 1,639 hepatectomies for non-colorectal non-neuroendocrine liver metastases: a multicenter analysis. J. Hepatobiliary Pancreat. Sci. 25, 465–475 (2018).
pubmed: 30311741
doi: 10.1002/jhbp.587
Lai, Q. et al. Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in East and West. J. Hepatol. 57, 974–979 (2012).
pubmed: 22771712
doi: 10.1016/j.jhep.2012.06.033
He, S. et al. Effect of prophylactic TACE on 5-year survival of patients with hepatocellular carcinoma after hepatectomy. Oncol. Lett. 18, 1824–1830 (2019).
pubmed: 31423250
pmcid: 6614664
Ogata, S. et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br. J. Surg. 93, 1091–1098 (2006).
pubmed: 16779884
doi: 10.1002/bjs.5341
Shim, J. H. et al. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann. Surg. Oncol. 17, 869–877 (2010).
pubmed: 20033326
doi: 10.1245/s10434-009-0788-7
Vigano, L. et al. Minor hepatectomies: focusing a blurred picture: analysis of the outcome of 4471 open resections in patients without cirrhosis. Ann. Surg. 270, 842–851 (2019).
pubmed: 31569127
doi: 10.1097/SLA.0000000000003493
Mise, Y. et al. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Ann. Surg. 263, 146–152 (2016).
pubmed: 25775068
doi: 10.1097/SLA.0000000000001194
Kobayashi, K. et al. Parenchyma-sparing liver resection for hepatocellular carcinoma in left lateral section is associated with better liver volume recovery. HPB 20, 949–955 (2018).
pubmed: 30007534
doi: 10.1016/j.hpb.2018.03.020
Torzilli, G. et al. Hepatic vein management in a parenchyma-sparing policy for resecting colorectal liver metastases at the caval confluence. Surgery 163, 277–284 (2018).
pubmed: 29169612
doi: 10.1016/j.surg.2017.09.003
Famularo, S. et al. Long-term oncologic results of anatomic vs. parenchyma-sparing resection for hepatocellular carcinoma. A propensity score-matching analysis. Eur. J. Surg. Oncol. 44, 1580–1587 (2018).
pubmed: 29861336
doi: 10.1016/j.ejso.2018.05.018
Moris, D. et al. Parenchymal-sparing versus anatomic liver resection for colorectal liver metastases: a systematic review. J. Gastrointest. Surg. 21, 1076–1085 (2017).
pubmed: 28364212
doi: 10.1007/s11605-017-3397-y
Lordan, J. T. et al. Case-controlled study comparing peri-operative and cancer-related outcomes after major hepatectomy and parenchymal sparing hepatectomy for metastatic colorectal cancer. HPB 19, 688–694 (2017).
pubmed: 28495437
doi: 10.1016/j.hpb.2017.04.007
Kalil, J. A. et al. Laparoscopic parenchymal-sparing hepatectomy: the new maximally minimal invasive surgery of the liver-a systematic review and meta-analysis. J. Gastrointest. Surg. 23, 860–869 (2019).
pubmed: 30756316
doi: 10.1007/s11605-019-04128-w
Rous, P. & Larimore, L. D. Relation of the portal blood to liver maintenance: a demonstration of liver atrophy conditional on compensation. J. Exp. Med. 31, 609–632 (1920).
pubmed: 19868417
pmcid: 2128242
doi: 10.1084/jem.31.5.609
Makuuchi, M. et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 107, 521–527 (1990).
pubmed: 2333592
pmcid: 2333592
Adam, R., Laurent, A., Azoulay, D., Castaing, D. & Bismuth, H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann. Surg. 232, 777–785 (2000).
pubmed: 11088072
pmcid: 1421270
doi: 10.1097/00000658-200012000-00006
Jaeck, D. et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann. Surg. 240, 1037–1049 (2004). This article first reported a two-stage hepatectomy strategy combined with portal vein embolization to convert unresectable scenarios into resectable scenarios.
pubmed: 15570209
pmcid: 1356519
doi: 10.1097/01.sla.0000145965.86383.89
Kianmanesh, R. et al. Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J. Am. Coll. Surg. 197, 164–170 (2003).
pubmed: 12831938
doi: 10.1016/S1072-7515(03)00334-X
Kawaguchi, Y., Lillemoe, H. A. & Vauthey, J. N. Dealing with an insufficient future liver remnant: portal vein embolization and two-stage hepatectomy. J. Surg. Oncol. 119, 594–603 (2019).
pubmed: 30825223
pmcid: 6422720
doi: 10.1002/jso.25430
Elias, D. et al. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br. J. Surg. 86, 784–788 (1999).
pubmed: 10383579
doi: 10.1046/j.1365-2168.1999.01154.x
Heinrich, S., Jochum, W., Graf, R. & Clavien, P. A. Portal vein ligation and partial hepatectomy differentially influence growth of intrahepatic metastasis and liver regeneration in mice. J. Hepatol. 45, 35–42 (2006).
pubmed: 16698111
doi: 10.1016/j.jhep.2006.02.020
Esposito, F. et al. Combined hepatic and portal vein embolization as preparation for major hepatectomy: a systematic review. HPB 21, 1099–1106 (2019).
pubmed: 30926329
doi: 10.1016/j.hpb.2019.02.023
Chiche, L. et al. Radiological simultaneous porto-hepatic vein embolization (RASPE) before major hepatectomy: a better way to optimize liver hypertrophy compared to portal vein embolization. Ann. Surg. https://doi.org/10.1097/SLA.0000000000003905 (2020).
doi: 10.1097/SLA.0000000000003905
pubmed: 32675481
Clavien, P. A. Hepatic vein embolization for safer liver surgery insignificant novelty or a breakthrough? Ann. Surg. https://doi.org/10.1097/SLA.0000000000003973 (2020).
doi: 10.1097/SLA.0000000000003973
pubmed: 32925252
Schnitzbauer, A. A. et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann. Surg. 255, 405–414 (2012). This article reports, for the first time, that additional in situ splitting results in rapid and efficient hypertrophy in a two-stage hepatectomy approach.
pubmed: 22330038
doi: 10.1097/SLA.0b013e31824856f5
Lang, H. et al. 10th anniversary of ALPPS-lessons learned and quo vadis. Ann. Surg. 269, 114–119 (2019).
pubmed: 29727331
doi: 10.1097/SLA.0000000000002797
de Santibanes, E. & Clavien, P. A. Playing Play-Doh to prevent postoperative liver failure: the “ALPPS” approach. Ann. Surg. 255, 415–417 (2012).
pubmed: 22330039
doi: 10.1097/SLA.0b013e318248577d
Linecker, M. et al. Risk adjustment in ALPPS is associated with a dramatic decrease in early mortality and morbidity. Ann. Surg. 266, 779–786 (2017).
pubmed: 28806301
doi: 10.1097/SLA.0000000000002446
Wang, Z. et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients. Ann. Surg. 271, 534–541 (2020).
pubmed: 29995681
doi: 10.1097/SLA.0000000000002942
Linecker, M. et al. ALPPS in neuroendocrine liver metastases not amenable for conventional resection - lessons learned from an interim analysis of the International ALPPS Registry. HPB 22, 537–544 (2020).
pubmed: 31540885
doi: 10.1016/j.hpb.2019.08.011
Li, J. et al. ALPPS for locally advanced intrahepatic cholangiocarcinoma: did aggressive surgery lead to the oncological benefit? An international multi-center study. Ann. Surg. Oncol. 27, 1372–1384 (2020).
pubmed: 32002719
pmcid: 7138775
doi: 10.1245/s10434-019-08192-z
Truant, S. et al. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): impact of the inter-stages course on morbi-mortality and implications for management. Eur. J. Surg. Oncol. 41, 674–682 (2015).
pubmed: 25630689
doi: 10.1016/j.ejso.2015.01.004
Kremer, M. et al. Impact of neoadjuvant chemotherapy on hypertrophy of the future liver remnant after associating liver partition and portal vein ligation for staged hepatectomy. J. Am. Coll. Surg. 221, 717–728.e1 (2015).
pubmed: 26232303
doi: 10.1016/j.jamcollsurg.2015.05.017
Schadde, E. et al. Early survival and safety of ALPPS: first report of the international ALPPS registry. Ann. Surg. 260, 829–836 (2014).
pubmed: 25379854
doi: 10.1097/SLA.0000000000000947
Raptis, D. A. et al. Defining Benchmark Outcomes for ALPPS. Ann. Surg. 270, 835–841 (2019).
pubmed: 31592812
doi: 10.1097/SLA.0000000000003539
Eshmuminov, D. et al. Meta-analysis of associating liver partition with portal vein ligation and portal vein occlusion for two-stage hepatectomy. Br. J. Surg. 103, 1768–1782 (2016).
pubmed: 27633328
doi: 10.1002/bjs.10290
Sandstrom, P. et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a scandinavian multicenter randomized controlled trial (LIGRO Trial). Ann. Surg. 267, 833–840 (2018).
pubmed: 28902669
doi: 10.1097/SLA.0000000000002511
Hasselgren, K., Røsok, B. I., Sparrelid, E., Sandström, P. ALPPS improves survival compared with TSH in patients affected of CRLM — survival analysis from the randomized controlled trial LIGRO. Ann. Surg. https://doi.org/10.1097/SLA.0000000000003701 (2019). This randomized trial demonstrates in patients with CRLM significantly superior survival after ALPPS than after two-stage hepatectomy.
Li, J. et al. Avoid “All-Touch” by hybrid ALPPS to achieve oncological efficacy. Ann. Surg. 263, e6–e7 (2016).
pubmed: 25072445
doi: 10.1097/SLA.0000000000000845
Linecker, M. et al. How much liver needs to be transected in ALPPS? A translational study investigating the concept of less invasiveness. Surgery 161, 453–464 (2017).
pubmed: 27814957
doi: 10.1016/j.surg.2016.08.004
Petrowsky, H., Gyori, G., de Oliveira, M., Lesurtel, M. & Clavien, P. A. Is partial-ALPPS safer than ALPPS? A single-center experience. Ann. Surg. 261, e90–e92 (2015).
pubmed: 25706390
doi: 10.1097/SLA.0000000000001087
Machado, M. A., Makdissi, F. F. & Surjan, R. C. Totally laparoscopic ALPPS is feasible and may be worthwhile. Ann. Surg. 256, e13 (2012).
pubmed: 22842130
doi: 10.1097/SLA.0b013e318265ff2e
Robles, R. et al. Tourniquet modification of the associating liver partition and portal ligation for staged hepatectomy procedure. Br. J. Surg. 101, 1129–1134 (2014).
pubmed: 24947768
doi: 10.1002/bjs.9547
de Santibanes, E., Alvarez, F. A., Ardiles, V., Pekolj, J. & de Santibanes, M. Inverting the ALPPS paradigm by minimizing first stage impact: the Mini-ALPPS technique. Langenbecks Arch. Surg. 401, 557–563 (2016).
pubmed: 27084508
doi: 10.1007/s00423-016-1424-1
Rosok, B. I. et al. Characterization of early recurrences following liver resection by ALPPS and two stage hepatectomy in patients with colorectal liver-metastases and small future liver remnants; a translational substudy of the LIGRO-RCT. HPB 21, 1017–1023 (2019).
pubmed: 30765198
doi: 10.1016/j.hpb.2018.12.003
Linecker, M., Kuemmerli, C., Clavien, P. A. & Petrowsky, H. Dealing with insufficient liver remnant: associating liver partition and portal vein ligation for staged hepatectomy. J. Surg. Oncol. 119, 604–612 (2019).
pubmed: 30847941
doi: 10.1002/jso.25435
Mentha, G. et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br. J. Surg. 93, 872–878 (2006).
pubmed: 16671066
doi: 10.1002/bjs.5346
Clavien, P. A. & Barkun, J. Consensus conference on laparoscopic liver resection: a jury-based evaluation. Ann. Surg. 261, 630–631 (2015).
pubmed: 25742462
doi: 10.1097/SLA.0000000000001183
Wakabayashi, G. et al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann. Surg. 261, 619–629 (2015). International Consensus Conference on Laparoscopic Liver Resections to evaluate the current status of laparoscopic liver surgery and to provide recommendations to aid its future development.
pubmed: 25742461
Abu Hilal, M. et al. The southampton consensus guidelines for laparoscopic liver surgery: from indication to implementation. Ann. Surg. 268, 11–18 (2018).
pubmed: 29064908
doi: 10.1097/SLA.0000000000002524
Fruscione, M. et al. Robotic-assisted versus laparoscopic major liver resection: analysis of outcomes from a single center. HPB 21, 906–911 (2019).
pubmed: 30617001
doi: 10.1016/j.hpb.2018.11.011
Fahrner, R. et al. Robotic hepatic surgery in malignancy: review of the current literature. J. Robot. Surg. 13, 533–538 (2019).
pubmed: 30895519
doi: 10.1007/s11701-019-00939-w
Kim, J. K. et al. Robotic versus laparoscopic left lateral sectionectomy of liver. Surg. Endosc. 30, 4756–4764 (2016).
pubmed: 26902613
doi: 10.1007/s00464-016-4803-3
Salloum, C. et al. Robotic-assisted versus laparoscopic left lateral sectionectomy: analysis of surgical outcomes and costs by a propensity score matched cohort study. World J. Surg. 41, 516–524 (2017).
pubmed: 27743071
doi: 10.1007/s00268-016-3736-2
Chen, P. D. et al. Robotic versus open hepatectomy for hepatocellular carcinoma: a matched comparison. Ann. Surg. Oncol. 24, 1021–1028 (2017).
pubmed: 27778128
doi: 10.1245/s10434-016-5638-9
Chen, P. D. et al. Robotic major hepatectomy: is there a learning curve? Surgery 161, 642–649 (2017).
pubmed: 27884614
doi: 10.1016/j.surg.2016.09.025
Barkun, J. S., Dimick, J. B. & Clavien, P. A. Surgical research in patients: ideal time for an IDEAL checklist. Ann. Surg. 269, 208–210 (2019).
pubmed: 30615599
doi: 10.1097/SLA.0000000000003140
Hirst, A. et al. No surgical innovation without evaluation: evolution and further development of the IDEAL framework and recommendations. Ann. Surg. 269, 211–220 (2019).
pubmed: 29697448
doi: 10.1097/SLA.0000000000002794
Halls, M. C. et al. A comparison of the learning curves of laparoscopic liver surgeons in differing stages of the IDEAL paradigm of surgical innovation: standing on the shoulders of pioneers. Ann. Surg. 269, 221–228 (2019).
pubmed: 30080729
doi: 10.1097/SLA.0000000000002996
Rogers, W. A., Hutchison, K. & McNair, A. Ethical issues across the IDEAL stages of surgical innovation. Ann. Surg. 269, 229–233 (2019).
pubmed: 30614842
doi: 10.1097/SLA.0000000000003106
Cortolillo, N., Patel, C., Parreco, J., Kaza, S. & Castillo, A. Nationwide outcomes and costs of laparoscopic and robotic vs. open hepatectomy. J. Robot. Surg. 13, 557–565 (2019).
pubmed: 30484059
doi: 10.1007/s11701-018-0896-0
Cillo, U. et al. Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: results of 815 procedures. J. Surg. Oncol. 120, 956–965 (2019).
pubmed: 31373009
doi: 10.1002/jso.25651
Cornelis, F. H. & Solomon, S. B. Treatment of primary liver tumors and liver metastases, part 2: non-nuclear medicine techniques. J. Nucl. Med. 59, 1801–1808 (2018).
pubmed: 30361378
pmcid: 6278901
doi: 10.2967/jnumed.116.186379
Giglio, M. C. et al. Laparoscopic versus open thermal ablation of colorectal liver metastases: a propensity score-based analysis of local control of the ablated tumors. Ann. Surg. Oncol. https://doi.org/10.1245/s10434-020-08243-w (2020).
doi: 10.1245/s10434-020-08243-w
pubmed: 32060758
Ringe, K. I. et al. Experimental evaluation of the heat sink effect in hepatic microwave ablation. PLoS One 10, e0134301 (2015).
pubmed: 26222431
pmcid: 4519107
doi: 10.1371/journal.pone.0134301
Schramm, W., Yang, D., Wood, B. J., Rattay, F. & Haemmerich, D. Contribution of direct heating, thermal conduction and perfusion during radiofrequency and microwave ablation. Open Biomed. Eng. J. 1, 47–52 (2007).
pubmed: 19662127
pmcid: 2701080
doi: 10.2174/1874120700701010047
Ahmed, M., Brace, C. L., Lee, F. T. Jr & Goldberg, S. N. Principles of and advances in percutaneous ablation. Radiology 258, 351–369 (2011).
pubmed: 21273519
pmcid: 6939957
doi: 10.1148/radiol.10081634
Ding, J. et al. Complications of thermal ablation of hepatic tumours: comparison of radiofrequency and microwave ablative techniques. Clin. Radiol. 68, 608–615 (2013).
pubmed: 23399463
doi: 10.1016/j.crad.2012.12.008
Seror, O. Ablative therapies: advantages and disadvantages of radiofrequency, cryotherapy, microwave and electroporation methods, or how to choose the right method for an individual patient? Diagn. Interv. Imaging 96, 617–624 (2015). This article points out the advantages of each ablation technique, highlighting important differences in their technologies and how to transfer this concept into clinical practice.
pubmed: 25981214
doi: 10.1016/j.diii.2015.04.007
Adam, R. et al. Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery? Ann. Surg. 253, 349–359 (2011).
pubmed: 21178761
doi: 10.1097/SLA.0b013e318207bf2c
Loveman, E. et al. The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. Health Technol. Assess. 18, 1–283 (2014).
doi: 10.3310/hta18070
Faitot, F. et al. Two-stage hepatectomy versus 1-stage resection combined with radiofrequency for bilobar colorectal metastases: a case-matched analysis of surgical and oncological outcomes. Ann. Surg. 260, 822–827 (2014). This study compares the long-term follow-up of two surgical strategies for patients with bilobar CRLM. It demonstrates that the one-stage strategy combining resection with radiofrequency ablation is a good option in the treatment of such patients.
pubmed: 25379853
doi: 10.1097/SLA.0000000000000976
Park, H. M. et al. Outcomes for patients with recurrent intrahepatic cholangiocarcinoma after surgery. Ann. Surg. Oncol. 23, 4392–4400 (2016).
pubmed: 27581609
doi: 10.1245/s10434-016-5454-2
Yin, X. Y. et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer 115, 1914–1923 (2009).
pubmed: 19241423
doi: 10.1002/cncr.24196
Lee, M. W. et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a 10-year intention-to-treat analysis. Hepatology 65, 1979–1990 (2017).
pubmed: 28170115
doi: 10.1002/hep.29098
Kim, Y. S. et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J. Hepatol. 58, 89–97 (2013).
pubmed: 23023009
doi: 10.1016/j.jhep.2012.09.020
Feng, K. et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J. Hepatol. 57, 794–802 (2012).
pubmed: 22634125
doi: 10.1016/j.jhep.2012.05.007
Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450–1462 (2019).
pubmed: 30970190
doi: 10.1056/NEJMra1713263
Davalos, R. V., Mir, I. L. & Rubinsky, B. Tissue ablation with irreversible electroporation. Ann. Biomed. Eng. 33, 223–231 (2005).
pubmed: 15771276
doi: 10.1007/s10439-005-8981-8
Dollinger, M. et al. Bile duct injury after irreversible electroporation of hepatic malignancies: evaluation of MR imaging findings and laboratory values. J. Vasc. Interv. Radiol. 27, 96–103 (2016).
pubmed: 26777402
doi: 10.1016/j.jvir.2015.10.002
Kambakamba, P. et al. Intraoperative adverse events during irreversible electroporation-a call for caution. Am. J. Surg. 212, 715–721 (2016).
pubmed: 27712669
doi: 10.1016/j.amjsurg.2016.07.001
Scheffer, H. J. et al. Colorectal liver metastatic disease: efficacy of irreversible electroporation–a single-arm phase II clinical trial (COLDFIRE-2 trial). BMC Cancer 15, 772 (2015).
pubmed: 26497813
pmcid: 4619419
doi: 10.1186/s12885-015-1736-5
Cannon, R., Ellis, S., Hayes, D., Narayanan, G. & Martin, R. C. II. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J. Surg. Oncol. 107, 544–549 (2013).
pubmed: 23090720
doi: 10.1002/jso.23280
Cannon, R. M., Bolus, D. N. & White, J. A. Irreversible electroporation as a bridge to liver transplantation. Am. Surg. 85, 103–110 (2019).
pubmed: 30760354
doi: 10.1177/000313481908500141
Cheng, R. G., Bhattacharya, R., Yeh, M. M. & Padia, S. A. Irreversible electroporation can effectively ablate hepatocellular carcinoma to complete pathologic necrosis. J. Vasc. Interv. Radiol. 26, 1184–1188 (2015).
pubmed: 26119204
doi: 10.1016/j.jvir.2015.05.014
Mafeld, S. et al. Percutaneous irreversible electroporation (IRE) of hepatic malignancy: a bi-institutional analysis of safety and outcomes. Cardiovasc. Intervent. Radiol. 42, 577–583 (2019).
pubmed: 30465255
doi: 10.1007/s00270-018-2120-z
Coletti, L. et al. Safety and feasibility of electrochemotherapy in patients with unresectable colorectal liver metastases: a pilot study. Int. J. Surg. 44, 26–32 (2017).
pubmed: 28624558
doi: 10.1016/j.ijsu.2017.06.033
Gasljevic, G. et al. Histopathological findings in colorectal liver metastases after electrochemotherapy. PLoS One 12, e0180709 (2017).
pubmed: 28686650
pmcid: 5501591
doi: 10.1371/journal.pone.0180709
Funovics, J. M. et al. Primary hepatic cancer – the role of limited resection and total hepatectomy with orthotopic liver replacement. Hepatogastroenterology 35, 316–320 (1988).
pubmed: 2850984
Moris, D. et al. Liver transplantation for unresectable colorectal liver metastases: a systematic review. J. Surg. Oncol. 116, 288–297 (2017).
pubmed: 28513862
doi: 10.1002/jso.24671
Rosenbrook, W. Jr & Carney, R. E. Spectinomycin modification. I 7-EPI-9-deoxy-4(R)-dihydrospectinomycin. J. Antibiot. 28, 953–959 (1975).
doi: 10.7164/antibiotics.28.953
Bismuth, H., Majno, P. E. & Adam, R. Liver transplantation for hepatocellular carcinoma. Semin. Liver Dis. 19, 311–322 (1999).
pubmed: 10518310
doi: 10.1055/s-2007-1007120
Mazzaferro, V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334, 693–699 (1996).
pubmed: 8594428
doi: 10.1056/NEJM199603143341104
Clavien, P. A. et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 13, e11–e22 (2012).
pubmed: 22047762
doi: 10.1016/S1470-2045(11)70175-9
Wang, Z. Y., Geng, L. & Zheng, S. S. Current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation. Hepatobiliary Pancreat. Dis. Int. 14, 145–149 (2015).
pubmed: 25865686
doi: 10.1016/S1499-3872(15)60345-9
Sapisochin, G. & Bruix, J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat. Rev. Gastroenterol. Hepatol. 14, 203–217 (2017).
pubmed: 28053342
doi: 10.1038/nrgastro.2016.193
Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33, 1394–1403 (2001).
pubmed: 11391528
doi: 10.1053/jhep.2001.24563
Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am. J. Transpl. 7, 2587–2596 (2007).
doi: 10.1111/j.1600-6143.2007.01965.x
Yang, J. D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16, 589–604 (2019).
pubmed: 31439937
pmcid: 6813818
doi: 10.1038/s41575-019-0186-y
Muller, M., Bird, T. G. & Nault, J. C. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J. Hepatol. 72, 990–1002 (2020).
pubmed: 32044402
doi: 10.1016/j.jhep.2020.01.019
Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 71, 793–801 (2019).
pubmed: 31279902
doi: 10.1016/j.jhep.2019.06.021
Ma, X. L. et al. Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. Oncol. Lett. 15, 8396–8404 (2018).
pubmed: 29805574
pmcid: 5950517
Mazzaferro, V. et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 154, 128–139 (2018).
pubmed: 28989060
doi: 10.1053/j.gastro.2017.09.025
Cescon, M., Cucchetti, A., Ravaioli, M. & Pinna, A. D. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J. Hepatol. 58, 609–618 (2013).
pubmed: 23041304
doi: 10.1016/j.jhep.2012.09.021
Lesurtel, M., Mullhaupt, B., Pestalozzi, B. C., Pfammatter, T. & Clavien, P. A. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am. J. Transpl. 6, 2644–2650 (2006).
doi: 10.1111/j.1600-6143.2006.01509.x
Hassoun, Z., Gores, G. J. & Rosen, C. B. Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. Surg. Oncol. Clin. N. Am. 11, 909–921 (2002).
pubmed: 12607579
doi: 10.1016/S1055-3207(02)00036-4
Rosen, C. B., Heimbach, J. K. & Gores, G. J. Liver transplantation for cholangiocarcinoma. Transpl. Int. 23, 692–697 (2010).
pubmed: 20497401
doi: 10.1111/j.1432-2277.2010.01108.x
Darwish Murad, S. et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143, 88–98.e3 (2012).
pubmed: 22504095
doi: 10.1053/j.gastro.2012.04.008
Ethun, C. G. et al. Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann. Surg. 267, 797–805 (2018). The first intention-to-treat analysis in hilar cholangiocarcinoma to compare liver resection with liver transplantation in patients with the same tumour criteria (that is, <3 cm, lymph-node negative disease).
pubmed: 29064885
pmcid: 6002861
doi: 10.1097/SLA.0000000000002574
Resch, T. et al. Liver transplantation for hilar cholangiocarcinoma (h-CCA): is it the right time? Transl. Gastroenterol. Hepatol. 3, 38 (2018).
pubmed: 30148223
pmcid: 6087782
doi: 10.21037/tgh.2018.06.06
Sapisochin, G., Fernandez de Sevilla, E., Echeverri, J. & Charco, R. Liver transplantation for cholangiocarcinoma: current status and new insights. World J. Hepatol. 7, 2396–2403 (2015).
pubmed: 26464755
pmcid: 4598610
doi: 10.4254/wjh.v7.i22.2396
Sapisochin, G. et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology 64, 1178–1188 (2016).
pubmed: 27481548
doi: 10.1002/hep.28744
Sapisochin, G. et al. “Very early” intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am. J. Transpl. 14, 660–667 (2014).
doi: 10.1111/ajt.12591
Lunsford, K. E. et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol. Hepatol. 3, 337–348 (2018).
pubmed: 29548617
doi: 10.1016/S2468-1253(18)30045-1
Fujita, T. Liver transplantation for intrahepatic cholangiocarcinoma. Lancet 384, 1182 (2014).
pubmed: 25263672
doi: 10.1016/S0140-6736(14)61716-5
Hagness, M. et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann. Surg. 257, 800–806 (2013).
pubmed: 23360920
doi: 10.1097/SLA.0b013e3182823957
Line, P. D., Hagness, M., Berstad, A. E., Foss, A. & Dueland, S. A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept. Ann. Surg. 262, e5–e9 (2015). First report of RAPID, which combines regeneration of partial liver grafts followed by delayed resection of the remaining metastatic liver part.
pubmed: 25692361
doi: 10.1097/SLA.0000000000001165
Frilling, A. et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 15, e8–e21 (2014).
pubmed: 24384494
doi: 10.1016/S1470-2045(13)70362-0
Lim, C. et al. Liver transplantation for neuroendocrine tumors: what have we learned? Semin. Liver Dis. 38, 351–356 (2018).
pubmed: 30357772
doi: 10.1055/s-0038-1669936
Richards-Taylor, S. et al. Clinically significant differences in Ki-67 proliferation index between primary and metastases in resected pancreatic neuroendocrine tumors. Pancreas 46, 1354–1358 (2017).
pubmed: 28984786
doi: 10.1097/MPA.0000000000000933
Dawson, L. A. et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int. J. Radiat. Oncol. Biol. Phys. 53, 810–821 (2002).
pubmed: 12095546
doi: 10.1016/S0360-3016(02)02846-8
Wulf, J. et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 45, 838–847 (2006).
pubmed: 16982548
doi: 10.1080/02841860600904821
Guckenberger, M. et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther. Onkol. 190, 26–33 (2014).
pubmed: 24052011
doi: 10.1007/s00066-013-0450-y
Lax, I., Blomgren, H., Naslund, I. & Svanstrom, R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 33, 677–683 (1994).
pubmed: 7946448
doi: 10.3109/02841869409121782
Chang, D. T. et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117, 4060–4069 (2011).
pubmed: 21432842
doi: 10.1002/cncr.25997
Hoyer, M. et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 45, 823–830 (2006).
pubmed: 16982546
doi: 10.1080/02841860600904854
van der Pool, A. E. et al. Stereotactic body radiation therapy for colorectal liver metastases. Br. J. Surg. 97, 377–382 (2010).
pubmed: 20095016
doi: 10.1002/bjs.6895
Scorsetti, M. et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J. Cancer Res. Clin. Oncol. 141, 543–553 (2015).
pubmed: 25245052
doi: 10.1007/s00432-014-1833-x
Petrelli, F. et al. Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Radiother. Oncol. 129, 427–434 (2018). Systematic review of SBRT for CRC liver metastases showing an association between SBRT dose and local metastases control.
pubmed: 29997034
doi: 10.1016/j.radonc.2018.06.035
Klement, R. J. et al. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer 19, 173 (2019).
pubmed: 30808323
pmcid: 6390357
doi: 10.1186/s12885-019-5362-5
Toesca, D. A. et al. Central liver toxicity after SBRT: an expanded analysis and predictive nomogram. Radiother. Oncol. 122, 130–136 (2017).
pubmed: 27865544
doi: 10.1016/j.radonc.2016.10.024
Xi, M. et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 8, e63864 (2013).
pubmed: 23737955
pmcid: 3667854
doi: 10.1371/journal.pone.0063864
Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016).
pubmed: 27380959
doi: 10.1093/annonc/mdw235
Kroeze, S. G. et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat. Rev. 53, 25–37 (2017).
pubmed: 28056412
doi: 10.1016/j.ctrv.2016.11.013
Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2017).
pubmed: 27748397
doi: 10.1038/nri.2016.107
Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).
pubmed: 25754329
doi: 10.1038/nature14292
Vogel, A. et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 871–873 (2019).
pubmed: 31987361
doi: 10.1093/annonc/mdy510
Bujold, A. et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J. Clin. Oncol. 31, 1631–1639 (2013).
pubmed: 23547075
doi: 10.1200/JCO.2012.44.1659
Takeda, A. et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer 122, 2041–2049 (2016).
pubmed: 27062278
doi: 10.1002/cncr.30008
Bettinger, D. et al. Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: a propensity score analysis. Liver Cancer 8, 281–294 (2019).
pubmed: 31602371
doi: 10.1159/000490260
Yoon, S. M. et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. 4, 661–669 (2018). Randomized trial showing an overall survival benefit of TACE combined with SBRT compared to sorafenib in patients with advanced HCC showing macroscopic vascular invasion.
pubmed: 29543938
pmcid: 5885246
doi: 10.1001/jamaoncol.2017.5847
Uemura, T. et al. Stereotactic body radiation therapy: a new strategy for loco-regional treatment for hepatocellular carcinoma while awaiting liver transplantation. World J. Surg. 43, 886–893 (2019).
pubmed: 30361748
doi: 10.1007/s00268-018-4829-x
Sapisochin, G. et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J. Hepatol. 67, 92–99 (2017).
pubmed: 28257902
doi: 10.1016/j.jhep.2017.02.022
Wei, X. et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J. Clin. Oncol. 37, 2141–2151 (2019).
pubmed: 31283409
pmcid: 6698917
doi: 10.1200/JCO.18.02184
Mahadevan, A. et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J. Cancer 6, 1099–1104 (2015).
pubmed: 26516357
pmcid: 4615345
doi: 10.7150/jca.13032
Gkika, E. et al. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. BMC Cancer 17, 781 (2017).
pubmed: 29162055
pmcid: 5699184
doi: 10.1186/s12885-017-3788-1
Feng, M. et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. JAMA Oncol. 4, 40–47 (2018).
pubmed: 28796864
doi: 10.1001/jamaoncol.2017.2303
Frakulli, R. et al. Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review. Br. J. Radiol. 92, 20180688 (2019).
pubmed: 30673295
pmcid: 6580923
doi: 10.1259/bjr.20180688
Mancini, R. et al. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates. In Vivo 20, 711–714 (2006).
pubmed: 17203751
Bhooshan, N. et al. Pretreatment tumor volume as a prognostic factor in metastatic colorectal cancer treated with selective internal radiation to the liver using yttrium-90 resin microspheres. J. Gastrointest. Oncol. 7, 931–937 (2016).
pubmed: 28078116
pmcid: 5177578
doi: 10.21037/jgo.2016.06.15
Fendler, W. P. et al. Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. Eur. Radiol. 25, 2693–2700 (2015).
pubmed: 25721320
doi: 10.1007/s00330-015-3658-7
Wasan, H. S. et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 18, 1159–1171 (2017). Pooled analysis of three randomized trials showing that the addition of SIRT to first-line FOLFOX chemotherapy for patients with liver-only and liver-dominant mCRC did not improve overall survival compared with FOLFOX alone.
pubmed: 28781171
pmcid: 5593813
doi: 10.1016/S1470-2045(17)30457-6
Chow, P. K. H. et al. SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma. J. Clin. Oncol. 36, 1913–1921 (2018).
pubmed: 29498924
doi: 10.1200/JCO.2017.76.0892
Vilgrain, V. et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 18, 1624–1636 (2017).
pubmed: 29107679
doi: 10.1016/S1470-2045(17)30683-6
Braat, A. et al. Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc. Intervent. Radiol. 42, 413–425 (2019).
pubmed: 30603975
doi: 10.1007/s00270-018-2148-0
Lehmann, K., Rickenbacher, A., Weber, A., Pestalozzi, B. C. & Clavien, P. A. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann. Surg. 255, 237–247 (2012).
pubmed: 22041509
doi: 10.1097/SLA.0b013e3182356236
Nordlinger, B. et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371, 1007–1016 (2008). The EPOC trial set the standard for perioperative treatment of technically resectable CRLM.
pubmed: 18358928
pmcid: 18358928
doi: 10.1016/S0140-6736(08)60455-9
Primrose, J. et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial. Lancet Oncol. 15, 601–611 (2014).
pubmed: 24717919
doi: 10.1016/S1470-2045(14)70105-6
Valle, J. W. et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27 (Suppl. 5), v28–v37 (2016).
pubmed: 27664259
doi: 10.1093/annonc/mdw324
Primrose, J.N. et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J. Clin. Oncol. 35, 4006–4006 (2017).
doi: 10.1200/JCO.2017.35.15_suppl.4006
Stein, A. et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer 15, 564 (2015).
pubmed: 26228433
pmcid: 4520064
doi: 10.1186/s12885-015-1498-0
Bruix, J. et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 16, 1344–1354 (2015).
pubmed: 26361969
doi: 10.1016/S1470-2045(15)00198-9
Meyer, T. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol. Hepatol. 2, 565–575 (2017).
pubmed: 28648803
doi: 10.1016/S2468-1253(17)30156-5
Ricke, J. et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J. Hepatol. 71, 1164–1174 (2019).
pubmed: 31421157
doi: 10.1016/j.jhep.2019.08.006
Zhu, X. D. & Sun, H. C. Emerging agents and regimens for hepatocellular carcinoma. J. Hematol. Oncol. 12, 110 (2019).
pubmed: 31655607
pmcid: 6815423
doi: 10.1186/s13045-019-0794-6
Duffy, A. G. et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J. Hepatol. 66, 545–551 (2017).
pubmed: 27816492
doi: 10.1016/j.jhep.2016.10.029
Greten, T. F., Mauda-Havakuk, M., Heinrich, B., Korangy, F. & Wood, B. J. Combined locoregional-immunotherapy for liver cancer. J. Hepatol. 70, 999–1007 (2019).
pubmed: 30738077
pmcid: 6462230
doi: 10.1016/j.jhep.2019.01.027
Pavel, M. et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103, 172–185 (2016).
pubmed: 26731013
doi: 10.1159/000443167
Kaltsas, G. et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology 105, 245–254 (2017).
pubmed: 28253514
pmcid: 5637287
doi: 10.1159/000461583
Strosberg, J. et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017).
pubmed: 28076709
pmcid: 5895095
doi: 10.1056/NEJMoa1607427
Partelli, S. et al. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery 163, 761–767 (2018).
pubmed: 29284590
doi: 10.1016/j.surg.2017.11.007
Adam, R. et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat. Rev. 41, 729–741 (2015).
pubmed: 26417845
doi: 10.1016/j.ctrv.2015.06.006
Folprecht, G. et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 11, 38–47 (2010).
pubmed: 19942479
doi: 10.1016/S1470-2045(09)70330-4
Adam, R. et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17, 1225–1239 (2012).
pubmed: 22962059
pmcid: 3481888
doi: 10.1634/theoncologist.2012-0121
Ye, L. C. et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J. Clin. Oncol. 31, 1931–1938 (2013).
pubmed: 23569301
doi: 10.1200/JCO.2012.44.8308
Gruenberger, T. et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann. Oncol. 26, 702–708 (2015).
pubmed: 25538173
doi: 10.1093/annonc/mdu580
Geissler, M. et al. mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109). J. Clin. Oncol. 36, 3509–3509 (2018).
doi: 10.1200/JCO.2018.36.15_suppl.3509
Cremolini, C. et al. Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a randomized phase 2 clinical trial JAMA Oncol. 4, 529–536 (2018).
pubmed: 29450468
pmcid: 5885260
doi: 10.1001/jamaoncol.2017.5314
Heinemann, V. et al. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur. J. Cancer 51, 1927–1936 (2015).
pubmed: 26188850
doi: 10.1016/j.ejca.2015.06.116
Shindoh, J. et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann. Surg. Oncol. 20, 2493–2500 (2013).
pubmed: 23377564
doi: 10.1245/s10434-012-2864-7
Chun, Y. S., Laurent, A., Maru, D. & Vauthey, J. N. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 10, 278–286 (2009).
pubmed: 19261256
doi: 10.1016/S1470-2045(09)70064-6
Dienstmann, R., Salazar, R. & Tabernero, J. Molecular subtypes and the evolution of treatment decisions in metastatic colorectal cancer. Am. Soc. Clin. Oncol. Educ. Book 38, 231–238 (2018). This article provides an up-to-date overview of molecular subtyping and personalized systemic treatment of mCRC.
pubmed: 30231342
doi: 10.1200/EDBK_200929
Arnold, D. et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol. 28, 1713–1729 (2017).
pubmed: 28407110
pmcid: 6246616
doi: 10.1093/annonc/mdx175
Pietrantonio, F. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur. J. Cancer 51, 587–594 (2015).
pubmed: 25673558
doi: 10.1016/j.ejca.2015.01.054
Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N. Engl. J. Med. 381, 1632–1643 (2019).
pubmed: 31566309
doi: 10.1056/NEJMoa1908075
Kopetz, S. et al. Updated results of the BEACON CRC safety lead-in: encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAF
doi: 10.1200/JCO.2019.37.4_suppl.688
Corcoran, R. B. et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF
pubmed: 29431699
pmcid: 5882509
doi: 10.1158/2159-8290.CD-17-1226
Raghav, R. et al. Validation of HER2 amplification as a predictive biomarker for anti–epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precision Oncol. 3, 1–13 (2019).
Sartore-Bianchi, A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 17, 738–746 (2016).
pubmed: 27108243
doi: 10.1016/S1470-2045(16)00150-9
Le, D. et al. Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164. Ann. Oncol. 29 (Suppl. 5), V107 (2018).
doi: 10.1093/annonc/mdy149.020
Lenz, H.-J. J. et al. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Ann. Oncol. 29 (Suppl. 8), VIII714 (2018).
doi: 10.1093/annonc/mdy424.019
Le Roy, B. et al. Neoadjuvant chemotherapy initially unresectable intrahepatic cholangiocarcinoma. Br. J. Surg. 105, 839–847 (2018).
pubmed: 28858392
doi: 10.1002/bjs.10641
Jusakul, A. et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7, 1116–1135 (2017).
pubmed: 28667006
pmcid: 5628134
doi: 10.1158/2159-8290.CD-17-0368
Wainberg, Z. A. et al. Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial. J. Clin. Oncol. 37, 187–187 (2019).
doi: 10.1200/JCO.2019.37.4_suppl.187
Abou-Alfa, G. K. ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutatio. Ann. Oncol. 30, v872–v873 (2019).
doi: 10.1093/annonc/mdz394.027
Vogel, A. FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA). Ann. Oncol. 30, v876 (2019).
doi: 10.1093/annonc/mdz394.031
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
pubmed: 18650514
doi: 10.1056/NEJMoa0708857
Ikeda, M. et al. Abstract CT061: a phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results. Cancer Res. 79, CT061–CT061 (2019).
Llovet, J. M. et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study. J. Clin. Oncol. 37, TPS4152 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.TPS4152
Cheng, A.-L. LBA3 – IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann. Oncol. 30 (Suppl. 9), ix186–ix187 (2019).
doi: 10.1093/annonc/mdz446.002
Samaras, P. et al. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Ann. Surg. Oncol. 18, 1924–1931 (2011).
pubmed: 21207165
doi: 10.1245/s10434-010-1505-2
Konstantinidis, I. T. et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 122, 758–765 (2016).
pubmed: 26695839
doi: 10.1002/cncr.29824
Cucchetti, A. et al. Selective internal radiation therapy (SIRT) as conversion therapy for unresectable primary liver malignancies. Liver Cancer 5, 303–311 (2016).
pubmed: 27781202
pmcid: 5075901
doi: 10.1159/000449341
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F. & Blumgart, L. H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 230, 309–318 (1999).
pubmed: 10493478
pmcid: 1420876
doi: 10.1097/00000658-199909000-00004
Nordlinger, B. et al. Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77, 1254–1262 (1996).
pubmed: 8608500
doi: 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I
Mann, C. D., Metcalfe, M. S., Leopardi, L. N. & Maddern, G. J. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch. Surg. 139, 1168–1172 (2004).
pubmed: 15545561
doi: 10.1001/archsurg.139.11.1168
Balachandran, V. P. et al. A validated prognostic multigene expression assay for overall survival in resected colorectal cancer liver metastases. Clin. Cancer Res. 22, 2575–2582 (2016).
pubmed: 26733613
pmcid: 4978939
doi: 10.1158/1078-0432.CCR-15-1071
Pitroda, S. P. et al. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat. Commun. 9, 1793 (2018).
pubmed: 29728604
pmcid: 5935683
doi: 10.1038/s41467-018-04278-6
Mlecnik, B. et al. The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci. Transl Med. 8, 327ra326 (2016).
doi: 10.1126/scitranslmed.aad6352
Tie, J. et al. Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM). J. Clin. Oncol. 34, e15131 (2016).
doi: 10.1200/JCO.2016.34.15_suppl.e15131